Assessment of Potential for Chronic Liver Injury in Participants Treated

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05651204` - GABA Biomarkers in Dravet Syndrome
Withdrawn	`NCT02910297` - The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
Recruiting	`NCT04462770` - EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome	Phase 2
Completed	`NCT02896608` - Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
Withdrawn	`NCT05140122` - LEONIDaS Caregivers Study
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02091206` - A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT05472389` - Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome	N/A
Active, not recruiting	`NCT05626634` - Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	Phase 2
Recruiting	`NCT01858285` - Genetics of Epilepsy and Related Disorders
Recruiting	`NCT04614506` - Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
Recruiting	`NCT06118255` - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome	Phase 3
Recruiting	`NCT04611438` - Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome	Phase 3
Completed	`NCT02091375` - Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)	Phase 3
Completed	`NCT05364021` - Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Phase 1/Phase 2
Recruiting	`NCT06112275` - A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)	Phase 1/Phase 2
Withdrawn	`NCT03254680` - Turmeric as Treatment in Epilepsy	N/A
Withdrawn	`NCT02174094` - Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome	Phase 3
Terminated	`NCT02187809` - Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome	Phase 3

NCT number	NCT05044819
Study type	Interventional
Source	Jazz Pharmaceuticals
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 7, 2021
Completion date	March 31, 2028

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms